Artificial Intelligence and Machine Learning in Clinical Medicine, 2023
NEjM 388:1201-1208,1220, Haug,C.H. & Drazen,J.M., 2023
Improving Neurology Clinical Care with Natural Language Processing Tools
Neurol 101:1010-1018, Ge,W.,et al, 2023
Neuromyelitis Optica Spectrum Disorder
NEJM 387:631-639, Wingerchuk, D.M. & Lucchinetti, C.F., 2022
Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder
NEJM 381:614-625, Pittock, S.J.,et al, 2019
Area Postrema Syndrome
Neurol 91:e1642-e1651, Shosha, E.,et al, 2018
Monitoring long-term Efficacy of Fampridine in Gait-Impaired Patients with Multiple Sclerosis
Neurol 88:832-841, Filli, L.,et al, 2017
A 50-year-old Woman with SLE and a Tumefactive Lesion
Neurol 89:e140-e145, Choi, J.H.,et al, 2017
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Current Concept of Neuromyelitis Optica (NMO) and NMO Spectrum Disorders
JNNP doi:10.1136/JNNP-2012-302310, Jacob, A.,et al, 2012
Hiccups, Nausea, and Vomiting: Water Channels Under Attack
Lancet 375:394, Riphagen,J.,et al, 2010
Sustained-Release Oral Fampridine in Multiple Sclerosis: A Randomised, Double-Blind, Controlled Trial
Lancet 373:732-738, Goodman,A.D.,et al, 2009
4-Aminopyridine Toxicity with Unintentional Overdose in Four Patients with Multiple Sclerosis
Neurol 71:1833-1834, Burton,J.M.,et al, 2008
Diagnosis and Treatment of Neuromyelitis Optica
The Neurologist 13:2-11, Wingerchuk,D.M., 2007
Immune Reconstitution Inflammatory Syndrome in the CNS of HIV Infected Patients
Neurol 67:383-388, Venkataramana,A.,et al, 2006
A Randomized Trial of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome
Neurol 54:603-607, Sanders,D.B.,et al, 2000
Quantitative Assessment of Sustained-Release 4-Aminopyridine for Symptomatic Treatment of Multiple Sclerosis
Neurol 48:817-821, Schwid,S.R.,et al, 1997
Treatment with Oral 3, 4 Diaminopyridine Improves Leg Strength in Multiple Sclerosis Patients
Neurol 47:1457-1462, Bever,C.T.,et al, 1996
Lambert-Eaton Myasthenic Syndrome Presenting with Severe Respiratory Failure
Muscle & Nerve 19:1328-1333996., Nicolle,M.W.,et al, 1996
4-Aminopyridine in the Treatment of Patients with Multiple Sclerosis:Long-term Efficacy and Safety
Arch Neurol 51:292-296, Polman,C.H.,et al, 1994
The Effects of 4-Aminopyridine in MS Pts:Randomized, Placebo-Controlled, Double-Blind, Concentration-Controlled, Crossover
Neurol 44:1054-1059, Bever,C.T.,et al, 1994
The Effect of 4-Aminopyridine on Clinical Signs in Multiple Sclerosis
Ann Neurol 32:123-130, vanDiemen,H.A.M.,et al, 1992
4-Aminopyridine in Multiple Sclerosis:Prolonged Administration
Neurol 41:1344-1348, Stefoski,D.,et al, 1991
Orally Administered 4-Aminopyridine Improves Clinical Signs in Multiple Sclerosis
Ann Neurol 27:186-192, Davis,F.A.,et al, 1990
Preliminary Trial of 3, 4-Diaminopyridine in Patients with Multiple Sclerosis
Ann Neurol 27:421-427, Bever,C.T.,et al, 1990
3, 4-Diaminopyridine in the Treatment of Lambert-Eaton Myasthenic Syndrome
NEJM 321:1567-1571, 1607-16081989., McEvoy,K.M.,et al, 1989
4-Aminopyridine Improves Clinical Signs in Multiple Sclerosis
Ann Neurol 21:71-77, Stefoski,D.,et al, 1987
4-Aminopyridine-A New Drug Tested in the Treatment of Eaton-Lambert Syndrome
JNNP 40:1109, Lundh,H.,et al, 1977